Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lete-Cel in Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
NCT05993299Phase 2Completed
- Sponsor
- US WorldMeds
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- CAR-T Cells
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel in synovial sarcoma (SS) and myxoid round cell liposarcoma (MRCLPS), sponsored by US WorldMeds. Primary endpoint: Overall Response Rate at 36 months. Started Dec 2019; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT05993299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993299.